PUREVAX Recombinant FeLV is the first and only recombinant canarypox-vectored nonadjuvanted feline leukemia virus (FeLV) vaccine. Safe, effective, and pure without adjuvants. Here are a few of the many benefits of PUREVAX ® feline vaccines:

Only PUREVAX ® vaccines offer a complete line of nonadjuvanted feline vaccines. PUREVAX vaccines help protect both cats and kittens from dangerous and deadly diseases, and give veterinarians and cat owners the peace of mind of knowing their cats …

PUREVAX ® is the only fully adjuvant-free feline vaccine range and provides: Optimised safety profile with adjuvant-free protection for all components; Powerful immune response without adjuvant, thanks to its innovative canarypox technology for FeLV and rabies;

Aktive Immunisierung von Katzen ab einem Alter von 8 Wochen gegen Katzenleukose zur Verhinderung einer persistenten Virämie und klinischer Symptome der damit verbundenen Erkrankung. Beginn der Immunität: 2 Wochen nach der Grundimmunisierung. Dauer der Immunität: 1 Jahr nach der letzten Impfung. Keine.

This medicine is authorised for use in the European Union. Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website. Latest procedure affecting product information: This page was last updated on 19/12/2024.

PureVax ® Recombinant FeLV contains a non-adjuvanted lyophilized suspension of a recombinant vectored feline leukemia vaccine plus sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to feline leukemia.

No se ha observado ninguna interacción cuando PUREVAX ® FeLV ha sido administrada con otras vacunas felinas no adyuvadas de Boehringer Ingelheim. Restricciones de uso: Como no se ha realizado ningún estudio específico, la vacuna está contraindicada en hembras gestantes o lactantes. Presentación: 10 dosis (líquida). Información adicional:

The vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat.

PUREVAX FeLV vaccine provided an equivalent degree of protection from persistent antigenemia and integration of proviral DNA as the two killed adjuvanted FeLV vaccines.

This medicine is authorised for use in the European Union. Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia. Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website. English (EN) (81.94 KB - PDF)